It said that the issue of newer high-end stents being

raised by some cardiologists and corporate hospitals is only to "scuttle" the price capping.

"The clause 15 of the Drug Price Control Order (DPCO) clearly states that any manufacturer should apply about the new product with evidence for its superiority to fix the ceiling price. Moreover, the capping has not affected the companies but the profit margin of the parties involved in the supply chain," it said.

Noting that the doctors across the country had welcomed the NPPA decision, ADEH said only the select few for whom the profits matter more than affordable health care for the common masses, are "crying wolf" without any reason or scientific evidence.

ADEH also expressed shock that Indian Medical Association has not come out with an open stand on this issue.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)